SLDB vs. STTK, CRBP, CELC, ACRV, MACK, IMMP, STOK, PRQR, SYRS, and NGM
Should you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Shattuck Labs (STTK), Corbus Pharmaceuticals (CRBP), Celcuity (CELC), Acrivon Therapeutics (ACRV), Merrimack Pharmaceuticals (MACK), Immutep (IMMP), Stoke Therapeutics (STOK), ProQR Therapeutics (PRQR), Syros Pharmaceuticals (SYRS), and NGM Biopharmaceuticals (NGM). These companies are all part of the "medical" sector.
Shattuck Labs (NASDAQ:STTK) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
Shattuck Labs presently has a consensus target price of $20.00, indicating a potential upside of 108.77%. Solid Biosciences has a consensus target price of $18.25, indicating a potential upside of 92.11%. Given Solid Biosciences' higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Solid Biosciences.
Shattuck Labs has higher earnings, but lower revenue than Solid Biosciences. Shattuck Labs is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Shattuck Labs has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.
In the previous week, Shattuck Labs had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Shattuck Labs and 1 mentions for Solid Biosciences. Shattuck Labs' average media sentiment score of 1.45 beat Solid Biosciences' score of -0.19 indicating that Solid Biosciences is being referred to more favorably in the news media.
58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 9.5% of Shattuck Labs shares are held by company insiders. Comparatively, 19.3% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Solid Biosciences received 226 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 73.53% of users gave Shattuck Labs an outperform vote while only 67.47% of users gave Solid Biosciences an outperform vote.
Solid Biosciences has a net margin of 0.00% compared to Solid Biosciences' net margin of -5,268.44%. Shattuck Labs' return on equity of -62.11% beat Solid Biosciences' return on equity.
Summary
Solid Biosciences beats Shattuck Labs on 10 of the 17 factors compared between the two stocks.
Get Solid Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solid Biosciences Competitors List
Related Companies and Tools
